Hyperion Therapeutics prices IPO at $10.00, below the range

By
A A A

Hyperion Therapeutics, which is focused on the treatment of orphan diseases of the liver relating to the urea cycle, raised $50 million by offering 5 million shares at $10.00, below the range of $11.00 to $13.00. Because Hyperion had planned to offer only 4.2 million shares, there was no change in proceeds raised. Hyperion Therapeutics plans to list on the NASDAQ under the symbol HPTX. Leerink Swann and Cowen & Company acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: HPTX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

How to Save Money at Bars
How to Save Money at Bars           

Stocks

Referenced

100%

Most Active by Volume

44,823,339
  • $75.19 ▲ 0.28%
43,744,171
  • $3.44 ▼ 0.29%
42,340,022
  • $97.671 ▲ 0.66%
34,178,145
  • $17.62 ▼ 1.23%
34,028,998
  • $15.59 ▼ 0.19%
32,055,708
  • $21.23 ▼ 2.41%
31,539,235
  • $3.76 ▲ 0.80%
30,434,619
    $34.25 unch
As of 7/25/2014, 04:03 PM